BCM
OTLK icon

Bridgeway Capital Management’s Outlook Therapeutics OTLK Stock Holding History

Bridgeway Capital Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-863
Closed -$123K – 1444
2018
Q1 		$123K Hold
863
– – ﹤0.01% 1313
2017
Q4 		$179K Hold
863
– – ﹤0.01% 1288
2017
Q3 		$189K Hold
863
– – ﹤0.01% 1285
2017
Q2 		$139K Hold
863
– – ﹤0.01% 1334
2017
Q1 		$370K Buy
+863
New +$429K ﹤0.01% 1151

Other funds holding OTLK

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bridgeway Capital Management's OTLK Position: Q2 2018 in Review

Bridgeway Capital Management sold out of Outlook Therapeutics (OTLK) in Q2 2018, closing a stake of 863 shares — an estimated $123K sold.

Bridgeway Capital Management first reported a position in OTLK in Q1 2017 and held it in 5 quarters. The position peaked at $370K in Q1 2017. 11 funds tracked by Wall St. Rank hold OTLK as of Q2 2018.

  • Bridgeway Capital Management reported no remaining Outlook Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Bridgeway Capital Management sold 863 Outlook Therapeutics shares in Q2 2018, an estimated $123K.
  • Bridgeway Capital Management first reported a position in Outlook Therapeutics in Q1 2017 and held it in 5 quarters.
  • Bridgeway Capital Management's Outlook Therapeutics position peaked at $370K in Q1 2017.
  • 11 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2018.

Based on Bridgeway Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.